Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Related Content

Brief Version (N/A)
Full Version

Appendix E: Acronyms

Last Updated: October 26, 2016; Last Reviewed: October 26, 2016

Acronym/Abbreviation Full Name
3TC lamivudine
ABC abacavir
ACOG American College of Obstetricians and Gynecologists
ALT alanine aminotransferase
anti-HBc anti-hepatitis B core antibody
anti-HBS hepatitis B surface antibody
AOR adjusted odds ratio
AP antepartum
ART antiretroviral therapy
ARV antiretroviral
AST aspartate aminotransferase
ATV atazanavir
ATV/r atazanavir/ritonavir
AUC area under the curve
AZT zidovudine
BID twice daily
BMI body mass index
CBC complete blood count
CD4 CD4 T lymphocyte 
CDC  Centers for Disease Control and Prevention
CI confidence interval
Cmax  maximum plasma concentration
Cmin minimum plasma concentration
CNS  central nervous system
COBI  cobicistat 
CVS  chorionic villus sampling 
CYP  cytochrome P
CYP3A4  cytochrome P450 3A4 
d4T  stavudine 
ddI   didanosine 
DMPA  depot medroxyprogesterone acetate 
DRV darunavir 
DRV/r  darunavir/ritonavir
DSMB  Data and Safety Monitoring Board
DTG dolutegravir 
EC  enteric coated
ECG  electrocardiogram 
EFV efavirenz 
EMS ethyl methane sulfonate 
ETR  etravirine 
EVG  elvitegravir 
FDA  Food and Drug Administration 
FDC  fixed drug combination 
FPV  fosamprenavir 
FPV/r  fosamprenavir/ritonavir
FTC  emtricitabine 
gp  glycoprotein 
HAV  hepatitis A virus 
HBIG  hepatitis B immune globulin 
HBsAg hepatitis B surface antigen
HBV  hepatitis B virus 
HCV  hepatitis C virus 
HELLP  hemolysis, elevated liver enzymes, and low platelets 
HGC  hard gel capsule 
HR  hazard ratio 
HRSA  Health Resources and Services Administration
HSR  hypersensitivity reaction
IC50  inhibitory concentration 50% 
IDV
 indinavir
IDV/r  indinavir/ritonavir
IGF
 insulin-like growth factor 
IgG Immunoglobulin G
IP 
 intrapartum 
IQR 
 interquartile range 
IRIS 
 immune reconstitution inflammatory syndrome 
IUD 
 intrauterine device 
IV 
 intravenous/intravenously 
LPV 
 lopinavir 
LPV/r 
 lopinavir/ritonavir
MAC 
 Mycobacterium avium complex 
mtDNA   mitochondrial DNA
MVC  maraviroc 
NFV   nelfinavir 
NIH  National Institutes of Health 
NNRTI   non-nucleoside reverse transcriptase inhibitor/non-nucleoside analogue reverse transcriptase inhibitor 
NRTI nucleoside reverse transcriptase inhibitor/nucleoside analogue reverse transcriptase inhibitor
NtRTI  nucleotide analogue reverse transcriptase inhibitor 
NVP   nevirapine 
OC   oral contraceptive 
OI   opportunistic infection 
OR   odds ratio 
The Panel   The Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission 
PCP   Pneumocystis jirovecii pneumonia 
PCR  polymerase chain reaction 
PI   protease inhibitor 
PK pharmacokinetic 
PO   orally 
PP  postpartum 
PPI  proton pump inhibitor 
PrEP   pre-exposure prophylaxis 
PTD   preterm delivery 
RAL   raltegravir 
RDS   respiratory distress syndrome 
RPV  rilpivirine
RR   relative risk 
RTV 
 ritonavir 
SD 
 single dose
SQ 
 subcutaneous
SQV 
 saquinavir 
SQV/r 
 saquinavir/ritonavir
STD 
 sexually transmitted disease
T20  enfuvirtide
TAF tenofovir alafenamide
TDF 
 tenofovir disoproxil fumarate 
TDM  therapeutic drug monitoring
TID 
 three times daily
TPV 
 tipranavir 
TPV/r 
 tipranavir/ritonavir
UGT 
 uridine diphosphate glucuronosyltransferase 
WHO 
 World Health Organization
ZDV
 zidovudine

Download Guidelines

Related Content

Email News letter Updates